SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-065567
Filing Date
2023-11-21
Accepted
2023-11-21 17:00:13
Documents
12
Period of Report
2023-11-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20231115.htm   iXBRL 8-K 42895
  Complete submission text file 0000950170-23-065567.txt   165884

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20231115_pre.xml EX-101.PRE 11445
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20231115.xsd EX-101.SCH 2464
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20231115_lab.xml EX-101.LAB 14719
6 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20231115_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 231429011
SIC: 2836 Biological Products, (No Diagnostic Substances)